Microbiome and metabolome features of the cardiometabolic disease spectrum

Research output: Contribution to journalJournal articlepeer-review

Standard

Microbiome and metabolome features of the cardiometabolic disease spectrum. / Fromentin, Sebastien; Forslund, Sofia K.; Chechi, Kanta; Aron-Wisnewsky, Judith; Chakaroun, Rima; Nielsen, Trine; Tremaroli, Valentina; Ji, Boyang; Prifti, Edi; Myridakis, Antonis; Chilloux, Julien; Andrikopoulos, Petros; Fan, Yong; Olanipekun, Michael T.; Alves, Renato; Adiouch, Solia; Bar, Noam; Talmor-Barkan, Yeela; Belda, Eugeni; Caesar, Robert; Coelho, Luis Pedro; Falony, Gwen; Fellahi, Soraya; Galan, Pilar; Galleron, Nathalie; Helft, Gerard; Hoyles, Lesley; Isnard, Richard; Le Chatelier, Emmanuelle; Julienne, Hanna; Olsson, Lisa; Pedersen, Helle Krogh; Pons, Nicolas; Quinquis, Benoit; Rouault, Christine; Roume, Hugo; Salem, Joe Elie; Schmidt, Thomas S.B.; Vieira-Silva, Sara; Li, Peishun; Zimmermann-Kogadeeva, Maria; Lewinter, Christian; Søndertoft, Nadja B.; Hansen, Tue H.; Gauguier, Dominique; Gøtze, Jens Peter; Køber, Lars; Kornowski, Ran; Vestergaard, Henrik; Hansen, Torben; Zucker, Jean Daniel; Hercberg, Serge; Letunic, Ivica; Bäckhed, Fredrik; Oppert, Jean Michel; Nielsen, Jens; Raes, Jeroen; Bork, Peer; Stumvoll, Michael; Segal, Eran; Clément, Karine; Dumas, Marc Emmanuel; Ehrlich, S. Dusko; Pedersen, Oluf.

In: Nature Medicine, Vol. 28, No. 2, 2022, p. 303-314.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Fromentin, S, Forslund, SK, Chechi, K, Aron-Wisnewsky, J, Chakaroun, R, Nielsen, T, Tremaroli, V, Ji, B, Prifti, E, Myridakis, A, Chilloux, J, Andrikopoulos, P, Fan, Y, Olanipekun, MT, Alves, R, Adiouch, S, Bar, N, Talmor-Barkan, Y, Belda, E, Caesar, R, Coelho, LP, Falony, G, Fellahi, S, Galan, P, Galleron, N, Helft, G, Hoyles, L, Isnard, R, Le Chatelier, E, Julienne, H, Olsson, L, Pedersen, HK, Pons, N, Quinquis, B, Rouault, C, Roume, H, Salem, JE, Schmidt, TSB, Vieira-Silva, S, Li, P, Zimmermann-Kogadeeva, M, Lewinter, C, Søndertoft, NB, Hansen, TH, Gauguier, D, Gøtze, JP, Køber, L, Kornowski, R, Vestergaard, H, Hansen, T, Zucker, JD, Hercberg, S, Letunic, I, Bäckhed, F, Oppert, JM, Nielsen, J, Raes, J, Bork, P, Stumvoll, M, Segal, E, Clément, K, Dumas, ME, Ehrlich, SD & Pedersen, O 2022, 'Microbiome and metabolome features of the cardiometabolic disease spectrum', Nature Medicine, vol. 28, no. 2, pp. 303-314. https://doi.org/10.1038/s41591-022-01688-4

APA

Fromentin, S., Forslund, S. K., Chechi, K., Aron-Wisnewsky, J., Chakaroun, R., Nielsen, T., Tremaroli, V., Ji, B., Prifti, E., Myridakis, A., Chilloux, J., Andrikopoulos, P., Fan, Y., Olanipekun, M. T., Alves, R., Adiouch, S., Bar, N., Talmor-Barkan, Y., Belda, E., ... Pedersen, O. (2022). Microbiome and metabolome features of the cardiometabolic disease spectrum. Nature Medicine, 28(2), 303-314. https://doi.org/10.1038/s41591-022-01688-4

Vancouver

Fromentin S, Forslund SK, Chechi K, Aron-Wisnewsky J, Chakaroun R, Nielsen T et al. Microbiome and metabolome features of the cardiometabolic disease spectrum. Nature Medicine. 2022;28(2):303-314. https://doi.org/10.1038/s41591-022-01688-4

Author

Fromentin, Sebastien ; Forslund, Sofia K. ; Chechi, Kanta ; Aron-Wisnewsky, Judith ; Chakaroun, Rima ; Nielsen, Trine ; Tremaroli, Valentina ; Ji, Boyang ; Prifti, Edi ; Myridakis, Antonis ; Chilloux, Julien ; Andrikopoulos, Petros ; Fan, Yong ; Olanipekun, Michael T. ; Alves, Renato ; Adiouch, Solia ; Bar, Noam ; Talmor-Barkan, Yeela ; Belda, Eugeni ; Caesar, Robert ; Coelho, Luis Pedro ; Falony, Gwen ; Fellahi, Soraya ; Galan, Pilar ; Galleron, Nathalie ; Helft, Gerard ; Hoyles, Lesley ; Isnard, Richard ; Le Chatelier, Emmanuelle ; Julienne, Hanna ; Olsson, Lisa ; Pedersen, Helle Krogh ; Pons, Nicolas ; Quinquis, Benoit ; Rouault, Christine ; Roume, Hugo ; Salem, Joe Elie ; Schmidt, Thomas S.B. ; Vieira-Silva, Sara ; Li, Peishun ; Zimmermann-Kogadeeva, Maria ; Lewinter, Christian ; Søndertoft, Nadja B. ; Hansen, Tue H. ; Gauguier, Dominique ; Gøtze, Jens Peter ; Køber, Lars ; Kornowski, Ran ; Vestergaard, Henrik ; Hansen, Torben ; Zucker, Jean Daniel ; Hercberg, Serge ; Letunic, Ivica ; Bäckhed, Fredrik ; Oppert, Jean Michel ; Nielsen, Jens ; Raes, Jeroen ; Bork, Peer ; Stumvoll, Michael ; Segal, Eran ; Clément, Karine ; Dumas, Marc Emmanuel ; Ehrlich, S. Dusko ; Pedersen, Oluf. / Microbiome and metabolome features of the cardiometabolic disease spectrum. In: Nature Medicine. 2022 ; Vol. 28, No. 2. pp. 303-314.

Bibtex

@article{525769535e574aecb7e085610f6930eb,
title = "Microbiome and metabolome features of the cardiometabolic disease spectrum",
abstract = "Previous microbiome and metabolome analyses exploring non-communicable diseases have paid scant attention to major confounders of study outcomes, such as common, pre-morbid and co-morbid conditions, or polypharmacy. Here, in the context of ischemic heart disease (IHD), we used a study design that recapitulates disease initiation, escalation and response to treatment over time, mirroring a longitudinal study that would otherwise be difficult to perform given the protracted nature of IHD pathogenesis. We recruited 1,241 middle-aged Europeans, including healthy individuals, individuals with dysmetabolic morbidities (obesity and type 2 diabetes) but lacking overt IHD diagnosis and individuals with IHD at three distinct clinical stages—acute coronary syndrome, chronic IHD and IHD with heart failure—and characterized their phenome, gut metagenome and serum and urine metabolome. We found that about 75% of microbiome and metabolome features that distinguish individuals with IHD from healthy individuals after adjustment for effects of medication and lifestyle are present in individuals exhibiting dysmetabolism, suggesting that major alterations of the gut microbiome and metabolome might begin long before clinical onset of IHD. We further categorized microbiome and metabolome signatures related to prodromal dysmetabolism, specific to IHD in general or to each of its three subtypes or related to escalation or de-escalation of IHD. Discriminant analysis based on specific IHD microbiome and metabolome features could better differentiate individuals with IHD from healthy individuals or metabolically matched individuals as compared to the conventional risk markers, pointing to a pathophysiological relevance of these features.",
author = "Sebastien Fromentin and Forslund, {Sofia K.} and Kanta Chechi and Judith Aron-Wisnewsky and Rima Chakaroun and Trine Nielsen and Valentina Tremaroli and Boyang Ji and Edi Prifti and Antonis Myridakis and Julien Chilloux and Petros Andrikopoulos and Yong Fan and Olanipekun, {Michael T.} and Renato Alves and Solia Adiouch and Noam Bar and Yeela Talmor-Barkan and Eugeni Belda and Robert Caesar and Coelho, {Luis Pedro} and Gwen Falony and Soraya Fellahi and Pilar Galan and Nathalie Galleron and Gerard Helft and Lesley Hoyles and Richard Isnard and {Le Chatelier}, Emmanuelle and Hanna Julienne and Lisa Olsson and Pedersen, {Helle Krogh} and Nicolas Pons and Benoit Quinquis and Christine Rouault and Hugo Roume and Salem, {Joe Elie} and Schmidt, {Thomas S.B.} and Sara Vieira-Silva and Peishun Li and Maria Zimmermann-Kogadeeva and Christian Lewinter and S{\o}ndertoft, {Nadja B.} and Hansen, {Tue H.} and Dominique Gauguier and G{\o}tze, {Jens Peter} and Lars K{\o}ber and Ran Kornowski and Henrik Vestergaard and Torben Hansen and Zucker, {Jean Daniel} and Serge Hercberg and Ivica Letunic and Fredrik B{\"a}ckhed and Oppert, {Jean Michel} and Jens Nielsen and Jeroen Raes and Peer Bork and Michael Stumvoll and Eran Segal and Karine Cl{\'e}ment and Dumas, {Marc Emmanuel} and Ehrlich, {S. Dusko} and Oluf Pedersen",
note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
doi = "10.1038/s41591-022-01688-4",
language = "English",
volume = "28",
pages = "303--314",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "nature publishing group",
number = "2",

}

RIS

TY - JOUR

T1 - Microbiome and metabolome features of the cardiometabolic disease spectrum

AU - Fromentin, Sebastien

AU - Forslund, Sofia K.

AU - Chechi, Kanta

AU - Aron-Wisnewsky, Judith

AU - Chakaroun, Rima

AU - Nielsen, Trine

AU - Tremaroli, Valentina

AU - Ji, Boyang

AU - Prifti, Edi

AU - Myridakis, Antonis

AU - Chilloux, Julien

AU - Andrikopoulos, Petros

AU - Fan, Yong

AU - Olanipekun, Michael T.

AU - Alves, Renato

AU - Adiouch, Solia

AU - Bar, Noam

AU - Talmor-Barkan, Yeela

AU - Belda, Eugeni

AU - Caesar, Robert

AU - Coelho, Luis Pedro

AU - Falony, Gwen

AU - Fellahi, Soraya

AU - Galan, Pilar

AU - Galleron, Nathalie

AU - Helft, Gerard

AU - Hoyles, Lesley

AU - Isnard, Richard

AU - Le Chatelier, Emmanuelle

AU - Julienne, Hanna

AU - Olsson, Lisa

AU - Pedersen, Helle Krogh

AU - Pons, Nicolas

AU - Quinquis, Benoit

AU - Rouault, Christine

AU - Roume, Hugo

AU - Salem, Joe Elie

AU - Schmidt, Thomas S.B.

AU - Vieira-Silva, Sara

AU - Li, Peishun

AU - Zimmermann-Kogadeeva, Maria

AU - Lewinter, Christian

AU - Søndertoft, Nadja B.

AU - Hansen, Tue H.

AU - Gauguier, Dominique

AU - Gøtze, Jens Peter

AU - Køber, Lars

AU - Kornowski, Ran

AU - Vestergaard, Henrik

AU - Hansen, Torben

AU - Zucker, Jean Daniel

AU - Hercberg, Serge

AU - Letunic, Ivica

AU - Bäckhed, Fredrik

AU - Oppert, Jean Michel

AU - Nielsen, Jens

AU - Raes, Jeroen

AU - Bork, Peer

AU - Stumvoll, Michael

AU - Segal, Eran

AU - Clément, Karine

AU - Dumas, Marc Emmanuel

AU - Ehrlich, S. Dusko

AU - Pedersen, Oluf

N1 - Publisher Copyright: © 2022, The Author(s).

PY - 2022

Y1 - 2022

N2 - Previous microbiome and metabolome analyses exploring non-communicable diseases have paid scant attention to major confounders of study outcomes, such as common, pre-morbid and co-morbid conditions, or polypharmacy. Here, in the context of ischemic heart disease (IHD), we used a study design that recapitulates disease initiation, escalation and response to treatment over time, mirroring a longitudinal study that would otherwise be difficult to perform given the protracted nature of IHD pathogenesis. We recruited 1,241 middle-aged Europeans, including healthy individuals, individuals with dysmetabolic morbidities (obesity and type 2 diabetes) but lacking overt IHD diagnosis and individuals with IHD at three distinct clinical stages—acute coronary syndrome, chronic IHD and IHD with heart failure—and characterized their phenome, gut metagenome and serum and urine metabolome. We found that about 75% of microbiome and metabolome features that distinguish individuals with IHD from healthy individuals after adjustment for effects of medication and lifestyle are present in individuals exhibiting dysmetabolism, suggesting that major alterations of the gut microbiome and metabolome might begin long before clinical onset of IHD. We further categorized microbiome and metabolome signatures related to prodromal dysmetabolism, specific to IHD in general or to each of its three subtypes or related to escalation or de-escalation of IHD. Discriminant analysis based on specific IHD microbiome and metabolome features could better differentiate individuals with IHD from healthy individuals or metabolically matched individuals as compared to the conventional risk markers, pointing to a pathophysiological relevance of these features.

AB - Previous microbiome and metabolome analyses exploring non-communicable diseases have paid scant attention to major confounders of study outcomes, such as common, pre-morbid and co-morbid conditions, or polypharmacy. Here, in the context of ischemic heart disease (IHD), we used a study design that recapitulates disease initiation, escalation and response to treatment over time, mirroring a longitudinal study that would otherwise be difficult to perform given the protracted nature of IHD pathogenesis. We recruited 1,241 middle-aged Europeans, including healthy individuals, individuals with dysmetabolic morbidities (obesity and type 2 diabetes) but lacking overt IHD diagnosis and individuals with IHD at three distinct clinical stages—acute coronary syndrome, chronic IHD and IHD with heart failure—and characterized their phenome, gut metagenome and serum and urine metabolome. We found that about 75% of microbiome and metabolome features that distinguish individuals with IHD from healthy individuals after adjustment for effects of medication and lifestyle are present in individuals exhibiting dysmetabolism, suggesting that major alterations of the gut microbiome and metabolome might begin long before clinical onset of IHD. We further categorized microbiome and metabolome signatures related to prodromal dysmetabolism, specific to IHD in general or to each of its three subtypes or related to escalation or de-escalation of IHD. Discriminant analysis based on specific IHD microbiome and metabolome features could better differentiate individuals with IHD from healthy individuals or metabolically matched individuals as compared to the conventional risk markers, pointing to a pathophysiological relevance of these features.

U2 - 10.1038/s41591-022-01688-4

DO - 10.1038/s41591-022-01688-4

M3 - Journal article

C2 - 35177860

AN - SCOPUS:85124750537

VL - 28

SP - 303

EP - 314

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 2

ER -

ID: 299198940